Name:
Human Hepatitis B Immunoglobulin (pH4) for Intravenous Injection
Use within:
36 months
Specifications:
Each vial contains 2000IU (40ml) anti-HBs.
Approval Number:
SFDA Approval No. S20083007
Indications:
Combination with lamivudine for the prevention of hepatitis B virus (HBV) re-infection in liver transplant patients.
Human Hepatitis B Immunoglobulin (pH4) for Intravenous Injection is a sterile solution of IgG antibodies derived from human plasma, specifically targeting the hepatitis B surface antigen. Produced via cold ethanol fractionation and pH 4 incubation to inactivate viruses, it serves as passive immunotherapy.
Contraindicated in patients with severe hypersensitivity to immunoglobulins or albumin. Must be stored at 2°C to 8°C; do not freeze. Administration requires monitoring for anaphylactic reactions and thrombotic events.